by James Radke, PhD and Joe Haddad | Oct 7, 2026
Nona Baker, Co-Chair of MPN Voice and patient, discusses her journey with essential thrombocythemia (ET) and polycythemia vera (PV), including diagnosis and treatment. ET is a condition characterized by an overproduction of platelets. Abnormal blood clotting...
by Madaline Spencer and Joe Haddad | Sep 3, 2026
The US Food and Drug Administration (FDA) has approved Mimrylo (rusfertide) for the treatment of adults with polycythemia vera (PV). PV is a condition characterized by an increased production of red blood cells. Affected people may also have excess white blood cells...
by Madaline Spencer and Joe Haddad | Aug 17, 2026
Ajay K. Nooka, MD, MPH, FACP, Director of the Myeloma Program at the Emory University School of Medicine, discusses topline results from the MonumenTAL-6 clinical trial testing Tecvayli (teclistamab) in adults with relapsed/refractory multiple myeloma (RRMM). ...
by Madaline Spencer and Joe Haddad | Apr 9, 2026
The US Food and Drug Administration (FDA) has approved Tecartus (brexucabtagene autoleucel) for the treatment of adults with relapsed or refractory (R/R) mantle cell lymphoma (MCL). MCL is a rare form of malignant non-Hodgkin lymphoma affecting B lymphocytes in the...
by Madaline Spencer and Joe Haddad | Mar 27, 2026
The US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage 3 or 4 classical Hodgkin lymphoma (cHL). The approval...
